Xilio Therapeutics, Inc. Common Stock — Institutional Ownership
Which tracked institutions hold XLO, and how they changed the position last quarter. Latest holdings as of Jun 30, 2026. Source: SEC 13-F filings.
8
Funds holding
$8004309
Total value held
Buying
4 added/new · 1 reduced
| # | Institution | Value | Shares | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | $6230727 | 650389 | — | Held |
| 2 | Merck & Co., Inc. | $1015308 | 105982 | — | Held |
| 3 | Morgan Stanley | $545619 | 56954 | -539 | -0.94% |
| 4 | State Street Corp | $127519 | 13311 | — | Held |
| 5 | Blackrock, Inc. | $83892 | 8757 | +8757 | NEW BUY |
| 6 | Barclays Plc | $1102 | 115 | +115 | NEW BUY |
| 7 | Ubs Group Ag | $134 | 14 | +14 | NEW BUY |
| 8 | Amalgamated Financial Corp. | $8 | 1078 | +1078 | NEW BUY |
Aggregated across tracked institutional filers. Reported quarterly on SEC Form 13-F and may lag. For research only — not investment advice.